Analyst Upgrade Signal: SYRE from Equal Weight to Overweight by Wells Fargo
Price Target: $12>>35
Report Date: 03-01-2024
Symbol: SYRE - Spyre Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Upgrade Signal: SYRE from Equal Weight to Overweight by Wells Fargo
Price Target: $12>>35
Spyre Therapeutics, Inc. (SYRE)
221 Crescent Street
Waltham, MA 02453
Phone: 617-651-5940
Website: https://www.spyre.com
CEO: Dr. Cameron Turtle DPHIL, Ph.D.
NASDAQ, NASDAQ Capital Market
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
best stock trading signals, stock option trading signals, free trading signals, stock trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228